Navigation Links
Staph stoppers

University of Iowa researchers have developed a new vaccine that protects against lethal pneumonia caused by Staphylococcus aureus (staph) bacteria, including drug-resistant strains like MRSA.

The research team was led by Patrick Schlievert, professor and chair of microbiology in the UI Carver College of Medicine. The findings are published this week in the Journal of Infectious Disease.

The new vaccine targets toxins that are made and secreted by staph bacteria. Earlier work by Schlievert's team found these toxins are responsible for the serious, sometimes deadly, symptoms produced by staph infections, including high fever, low blood pressure, and toxic shock. The researchers believed a vaccine that blocked the action of these toxins might prevent the serious illness caused by the bacteria.

Using an animal model that closely resembles human staph infection, the researchers showed that vaccination against three staph toxins provided almost complete protection against staph infections. The vaccinated animals were protected from disease even when they were infected with very high doses of bacteria. Furthermore, not only did the vaccine protect the animals from dying, but seven days after vaccination there were no disease-causing bacteria remaining in the animals' lungs.

"Our study suggests that vaccination against these toxins may provide protection against all strains of staph," Schlievert says. "If we can translate this finding into an effective vaccine for people it could potentially prevent millions of cases of serious and milder skin and soft tissue infections yearly."

The team also found that passive immunizationusing serum from vaccinated animals to immunize other animalswas successful. This finding suggests that antibodies induced by the vaccination are the protective factor.

According to the Centers for Disease Control and Prevention, Staphylococcus aureus bacteria are the most significant cause of serious infections and infection-related deaths in the Unites States. These bacteria cause many kinds of infections, from boils and other skin infections to life-threatening pneumonias and sepsis. Approximately 70,000 Americans develop staphylococcal pneumonia every year, including cases caused by highly antibiotic resistant MRSA strains. Many of these patients die from their illness, and many require extensive convalescence.

Previous attempts to develop vaccines have targeted proteins on the surface of staph bacteria, but these vaccines have not been successful. In the current study, Schlievert and his colleagues found that vaccination against bacterial cell-surface proteins actually increased the severity of the infection. In contrast, the new vaccine, which targets staph toxins, provided almost complete protection against staph infections.


Contact: Richard Lewis
University of Iowa

Related biology news :

1. Staphylococcus aureus bacteria turns immune system against itself
2. University of Wisconsin chemists find new compounds to curb staph infection
3. New compound overcomes drug-resistant Staph infection in mice
4. A drug used to treat HIV might defuse deadly staph infections
5. Sanctuary chimps show high rates of drug-resistant staph
6. Selenium suppresses staph on implant material
Post Your Comments:
(Date:6/7/2016)... 2016  Syngrafii Inc. and San Antonio Credit ... includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution ... will result in greater convenience for SACU members ... maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... ... on what they believe could be a new and helpful biomarker for malignant ... Click here to read it now. , Biomarkers are components in ...
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology: